ZyVersa Therapeutics Establishes Scientific Advisory Board for IC 100 Development in Obesity with Metabolic Issues

ZyVersa Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, announced the formation of a Scientific Advisory Board (SAB) to aid in the development of its inflammasome ASC inhibitor, IC 100, specifically for treating obesity and its associated metabolic complications. ZyVersa aims to leverage the extensive expertise of the SAB members in obesity, metabolic diseases, and inflammasomes to advance its clinical development program.

IC 100 is a novel humanized IgG4 monoclonal antibody designed to inhibit the inflammasome adaptor protein ASC. This protein plays a crucial role in the body's inflammatory response, and by targeting it, IC 100 aims to reduce both the initiation and perpetuation of inflammation. The drug acts by binding to ASC components of multiple inflammasome types, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, and Pyrin. By doing so, it inhibits the formation of ASC monomers and blocks the activation of IL-1β, a key mediator in the inflammatory cascade. This dual action of targeting both the initiation and perpetuation of inflammation makes IC 100 a promising candidate for treating various inflammatory diseases, with obesity and its metabolic complications being the primary indication.

ZyVersa’s new SAB includes five leading experts in obesity and metabolic diseases, alongside four leading inflammasome experts and inventors of IC 100 from the University of Miami Miller School of Medicine. This collaboration is expected to bring invaluable insights into the clinical development of IC 100, ensuring that the drug's development is grounded in the latest scientific research and clinical expertise.

The SAB members are distinguished professionals with extensive experience in their respective fields. They include:

- Caroline M. Apovian, MD: Co-Director at the Center for Weight Management and Wellness, Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School.

- Harold Bays, MD: Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center, and Clinical Associate Professor at the University of Louisville School of Medicine.

- Helen Bramlett, PhD: Professor in the Department of Neurological Surgery at the University of Miami Miller School of Medicine.

- Marc-Andre Cornier, MD: Professor of Medicine at the Medical University of South Carolina and Director of the Division of Endocrinology, Diabetes, and Metabolic Diseases.

- Juan Pablo de Rivero Vaccari, PhD: Associate Professor at the University of Miami Miller School of Medicine, involved with The Miami Project to Cure Paralysis.

- W. Dalton Dietrich, III, PhD: Scientific Director at The Miami Project to Cure Paralysis and Senior Associate Dean for Discovery Science at the University of Miami Miller School of Medicine.

- Robert W. Keane, PhD: Professor at the University of Miami Miller School of Medicine, specializing in Physiology, Biophysics, Neurological Surgery, and Microbiology.

- Samuel Klein, MD: William H. Danforth Professor of Medicine and Director of the Center for Human Nutrition at Washington University School of Medicine.

- Suneil Koliwad, MD, PhD: Chief of the Division of Endocrinology and Metabolism at UCSF Health and Gerold Grodsky Professor of Diabetes Research at UCSF.

ZyVersa Therapeutics, Inc. is dedicated to developing first-in-class drugs using advanced proprietary technologies to address high unmet medical needs in inflammatory and kidney diseases. Besides IC 100, which targets obesity with metabolic complications, the company is also working on VAR 200, a Cholesterol Efflux Mediator, for the treatment of focal segmental glomerulosclerosis (FSGS). Both therapeutic areas offer significant potential with a broad range of indications, representing a substantial market opportunity exceeding $100 billion.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!